Recent advances in systemic targeted therapy for cutaneous T-cell lymphoma

Daniel J Lewis^{1

2}, Ellen J Kim³, Madeleine Duvic²

Affiliations

¹ a School of Medicine , Baylor College of Medicine , Houston , TX , USA.
² b Department of Dermatology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
³ c Department of Dermatology, Perelman School of Medicine , University of Pennsylvania , Philadelphia , PA , USA.

Comment

Daniel J Lewis et al. Expert Opin Pharmacother. 2017 Oct.

. 2017 Oct;18(14):1535-1536.

doi: 10.1080/14656566.2017.1367594. Epub 2017 Aug 18.

Daniel J Lewis^{1

2}, Ellen J Kim³, Madeleine Duvic²

¹ a School of Medicine , Baylor College of Medicine , Houston , TX , USA.
² b Department of Dermatology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
³ c Department of Dermatology, Perelman School of Medicine , University of Pennsylvania , Philadelphia , PA , USA.

No abstract available

Comment in

Reply to 'Recent advances in systemic targeted therapy for cutaneous T-cell lymphoma'.
Amaral T, Garbe C. Amaral T, et al. Expert Opin Pharmacother. 2017 Oct;18(14):1537. doi: 10.1080/14656566.2017.1367596. Epub 2017 Aug 18. Expert Opin Pharmacother. 2017. PMID: 28812387 No abstract available.

Non-melanoma skin cancer: new and future synthetic drug treatments.
Amaral T, Garbe C. Amaral T, et al. Expert Opin Pharmacother. 2017 May;18(7):689-699. doi: 10.1080/14656566.2017.1316372. Epub 2017 Apr 17. Expert Opin Pharmacother. 2017. PMID: 28414587 Review.